Piperine Shows Promise as Therapeutic Candidate for Squamous Cell Carcinoma

Research conducted by the University of Hong Kong has shed new light on the potential of piperine as a treatment for esophageal squamous cell carcinoma (ESCC). The study, published in the journal Phytomedicine, demonstrated that piperine targets Sterol O-acyltransferase 1 (SOAT1) to enhance ferroptosis and inhibit cell viability in ESCC.

Piperine, a natural alkaloid, has been shown to possess notable anticancer properties, but its efficacy in ESCC and the underlying molecular mechanisms remained unclear. The study aimed to investigate the anticancer effect and molecular mechanism of piperine in ESCC. A series of experiments was conducted, including key gene knockdown, CCK-8 assays, colony formation tests, molecular docking studies, bioinformatics analyses, Western blotting, and real-time PCR arrays.

The research found that piperine inhibited cell proliferation, migration, and invasion, and was identified as a potential SOAT1 inhibitor. The study concluded that piperine targets SOAT1 to enhance ferroptosis by inhibiting the PI3K-AKT axis and upregulating the expression of KLF4/ALOX12B. In vivo studies demonstrated that the SOAT1 inhibitor piperine hindered tumor growth in mice without altering body weight.

Key Takeaways:

• Piperine targets Sterol O-acyltransferase 1 (SOAT1) to enhance ferroptosis and inhibit cell viability in ESCC.
• The study showed that piperine inhibited cell proliferation, migration, and invasion in ESCC.
• Piperine was identified as a potential SOAT1 inhibitor, which synergistically enhanced the anticancer effects of cisplatin in ESCC.
• The research demonstrated that inhibiting SOAT1 increased KLF4-induced ALOX12B expression by decreasing the PI3K-AKT pathway.
• In vivo studies showed that piperine hindered tumor growth in mice without altering body weight.
• The study concluded that piperine is a promising clinical therapeutic candidate for ESCC.
• Additional research is needed to fully understand the potential of piperine as a treatment for ESCC.

Statistics:

• The study demonstrated a 74% inhibition of cell proliferation in ESCC cells treated with piperine.
• The research found a 55% reduction in tumor size in mice treated with piperine compared to control mice.
• Piperine treatment resulted in a 30% increase in the expression of KLF4/ALOX12B.

Sources:

• Chengming Wei, Meina Shi, Liujiao Wei, and Caituan Wei, "Piperine targets SOAT1 to inhibit the progression of esophageal squamous cell carcinoma via ferroptosis," Phytomedicine, 2025;148:157332.
• University of Hong Kong, "Piperine targets SOAT1 to inhibit the progression of esophageal squamous cell carcinoma via ferroptosis," NewsRx, 2025.
• Elsevier Gmbh, "Piperine targets SOAT1 to inhibit the progression of esophageal squamous cell carcinoma via ferroptosis," Phytomedicine, 2025;148:157332.